AN2 Therapeutics Nominates HPP Development Candidate
The company said a novel boron-based oral ENPP1 inhibitor has advanced into development, with an oral profile tailored specifically for hypophosphatasia.
Related stories
Norwegian Air shares rise 5.2%, on track for best day since June
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Shringar House of Mangalsutra Reports Q2 Revenue of INR 8,186.6 Million
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Crédit Mutuel Arkéa Contains Cyberattack; Operations Gradually Resume
The bank said clients’ assets were not affected.
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Crédit Mutuel Arkéa Contains Cyberattack as Operations Gradually Resume
The bank said clients’ assets have not been affected.
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Crédit Mutuel Arkéa Says It Was Targeted in Cyberattack
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Circle Reports $865 Million in Q3 Revenue and Reserve Income
Circle reported third-quarter revenue and reserve income of $865 million, up 17% year over year. Net income from continuing operations was $226 million, compared with $214.4 millio
M impact | EQUITY | Nov 04, 2026, 01:21 PM UTC